Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$64.5MCash on Hand
10.5mo Cash Runway
Follow HUMA by emailGet an email when HUMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HUMA, unsubscribe in one click. Privacy
📣 What HUMA Says Is Next
in November 2026 · ATEV: “Based on these results, Humacyte plans to submit a supplemental Biologics License Application to the FDA in November 2026 to add dialysis access as a second approved indication.”
Company press release, Nov 10, 2026 · SEC filing
second half of 2026 · “Based on these results, Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026. · Appointed Key Nephrologists as Advisors to Prepare for Planned Dialysis Commercialization: Robert J. (Rob) Kossmann, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have been appointed as advisors to Humacyte.”
Company press release, Aug 12, 2026 · SEC filing
second half of 2026 · “Humacyte plans to file a supplemental BLA with the FDA during the second half of 2026 (target indication is in adult patients with ESKD who are at increased risk of AV fistula maturation failure). 40 41 Pipeline: Peripheral Arterial Disease (PAD)”
Company press release, Jun 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Q3 2026 Symvess sales reached $1.0 million, up 151% from Q2's $0.4 million, with 49 hospitals ordering as of September 30. October sales were $0.8 million, and Q4 sales are expected to at least double Q3. A supplemental BLA for dialysis access is planned for November 2026. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 28, 2026 ·
Leadership Humacyte appointed Scott Coward, a former Exact Sciences executive and current K&L Gates attorney, as a Class I director and Paul Kuznik, former CEO of Bolton Medical, as a Class II director. Each receives a $50,000 annual cash retainer and an option for 125,000 shares. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Clinical trial Reported Q2 2026 Symvess sales of $0.4 million versus $0.1 million a year earlier, and said it plans to file a supplemental BLA for dialysis access in the second half of 2026 after V012 Phase 3 interim results showed ATEV outperforming AV fistula (91 more catheter-free days, p=0.00070). Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 3 · Active Trial · To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Upcoming Trial · An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. Registry primary completion date, not a results date
Sep 2030 · Phase 4 · Upcoming Trial · Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent Repair Registry primary completion date, not a results date
Sep 2030 · Phase 2 · Upcoming Trial · Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HUMA holds $64.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.5M/quarter from operations,
an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:84 · High
Cash runway 10 months +30
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Sep 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 277,798,105 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HUMA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HUMA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.